{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:08:25Z","timestamp":1787501305919,"version":"build-2736575974"},"reference-count":45,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2018,10,18]]},"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      Tofacitinib is an oral Janus kinase inhibitor for treatment of psoriatic arthritis (PsA). We evaluated patient-reported outcomes (PROs) in patients with PsA refractory to \u22651 conventional synthetic disease-modifying antirheumatic drug (csDMARD-IR) and tumour necrosis factor inhibitor-na\u00efve in a 12-month, phase III randomised controlled trial (OPAL Broaden [\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01877668\">NCT01877668<\/jats:ext-link>\n                      ]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients (N=422) received tofacitinib 5 mg or 10 mg twice daily, adalimumab 40 mg subcutaneously every 2 weeks or placebo advancing to tofacitinib 5 mg or 10 mg twice daily at month 3. Least squares mean changes from baseline and percentages of patients reporting improvements \u2265minimum clinically important differences (MCID); and scores \u2265normative values in: Patient Global Assessment of disease activity (PtGA), Pain, Patient Global Joint and Skin Assessment (PGJS), Short Form-36 Health Survey version 2 (SF-36v2), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue), EuroQol 5-Dimensions-3-level questionnaire (EQ-5D-3L) and Ankylosing Spondylitis Quality of Life (ASQoL) were determined. Nominal p values were cited without multiple comparison adjustments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At month 3, PtGA, Pain, PGJS, FACIT-Fatigue, EQ-5D-3L, ASQoL and SF-36v2 Physical Component Summary (PCS), physical functioning (PF), bodily pain (BP) and vitality domain scores exceeded placebo with both tofacitinib doses (p\u22640.05); SF-36v2 social functioning with 5 mg twice daily (p\u22640.05). Percentages reporting improvements \u2265MCID in PtGA, Pain, PGJS, FACIT-Fatigue, ASQoL and SF-36v2 PCS, PF, BP and general health scores exceeded placebo with both tofacitinib doses (p\u22640.05) and were similar with adalimumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>csDMARD-IR patients with active PsA reported statistically and clinically meaningful improvements in PROs with tofacitinib compared with placebo at Month 3.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2018-000806","type":"journal-article","created":{"date-parts":[[2019,1,12]],"date-time":"2019-01-12T02:46:09Z","timestamp":1547261169000},"page":"e000806","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":52,"title":["Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden\u2014a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs"],"prefix":"10.1136","volume":"5","clinical-trial-number":[{"clinical-trial-number":"nct01877668","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01877668","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01882439","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01976364","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Vibeke","family":"Strand","sequence":"first","affiliation":[{"name":"Division of Immunology\/Rheumatology, Stanford University, Palo Alto, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"de Vlam","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A","family":"Covarrubias-Cobos","sequence":"additional","affiliation":[{"name":"Unidad Reumatologica Las Americas S.C.P., M\u00e9rida, Yucat\u00e1n, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J","family":"Mease","sequence":"additional","affiliation":[{"name":"Swedish Medical Center and University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna D","family":"Gladman","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Graham","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunshan","family":"Wang","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph C","family":"Cappelleri","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thijs","family":"Hendrikx","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Ann","family":"Hsu","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,1,11]]},"reference":[{"key":"2025090312360572000_5.1.e000806.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"2025090312360572000_5.1.e000806.2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-013-0032-x"},{"key":"2025090312360572000_5.1.e000806.3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40744-016-0029-z","article-title":"Psoriatic arthritis and burden of disease: patient perspectives from the population-based Multinational Assessment of Psoriasis and Psoriatic arthritis (MAPP) survey","volume":"3","author":"Kavanaugh","year":"2016","journal-title":"Rheumatol Ther"},{"key":"2025090312360572000_5.1.e000806.4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13075-017-1265-5","article-title":"Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis","volume":"19","author":"Bergman","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025090312360572000_5.1.e000806.5","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081015"},{"key":"2025090312360572000_5.1.e000806.6","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100857"},{"key":"2025090312360572000_5.1.e000806.7","first-page":"789","article-title":"The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales","volume":"9","author":"Fries","year":"1982","journal-title":"J Rheumatol"},{"key":"2025090312360572000_5.1.e000806.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"2025090312360572000_5.1.e000806.9","unstructured":"Ware JE , Kosinski M , Bjorner JB , et al . User's Manual for the Sf-36v2 Health Survey. 2nd edn. Lincoln, RI: Quality Metric Incorporated, 2007."},{"key":"2025090312360572000_5.1.e000806.10","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"2025090312360572000_5.1.e000806.11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170150"},{"key":"2025090312360572000_5.1.e000806.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975"},{"key":"2025090312360572000_5.1.e000806.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615977"},{"key":"2025090312360572000_5.1.e000806.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.034165"},{"key":"2025090312360572000_5.1.e000806.15","first-page":"400","article-title":"Looking for important change\/differences in studies of responsiveness. OMERACT MCID Working Group. Outcome measures in rheumatology. Minimal clinically important difference","volume":"28","author":"Beaton","year":"2001","journal-title":"J Rheumatol"},{"key":"2025090312360572000_5.1.e000806.16","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200203000-00006"},{"key":"2025090312360572000_5.1.e000806.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"2025090312360572000_5.1.e000806.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780360601"},{"key":"2025090312360572000_5.1.e000806.19","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110392"},{"key":"2025090312360572000_5.1.e000806.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200387"},{"key":"2025090312360572000_5.1.e000806.21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.065763"},{"key":"2025090312360572000_5.1.e000806.22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jval.2013.10.006","article-title":"From translation to version management: a history and review of methods for the cultural adaptation of the EuroQol five-dimensional questionnaire","volume":"17","author":"Rabin","year":"2014","journal-title":"Value Health"},{"key":"2025090312360572000_5.1.e000806.23","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.1.20"},{"key":"2025090312360572000_5.1.e000806.24","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.115550"},{"key":"2025090312360572000_5.1.e000806.25","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000308"},{"key":"2025090312360572000_5.1.e000806.26","doi-asserted-by":"publisher","DOI":"10.1002\/art.20048"},{"key":"2025090312360572000_5.1.e000806.27","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.143586"},{"key":"2025090312360572000_5.1.e000806.28","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121200"},{"key":"2025090312360572000_5.1.e000806.29","doi-asserted-by":"publisher","DOI":"10.3109\/03009740903468982"},{"key":"2025090312360572000_5.1.e000806.30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13075-018-1610-3","article-title":"Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study","volume":"20","author":"McInnes","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2025090312360572000_5.1.e000806.31","doi-asserted-by":"crossref","unstructured":"Mease P , Strand V , Gladman D . Functional impairment measurement in psoriatic arthritis: importance and challenges. Semin Arthritis Rheum 2018.doi:10.1016\/j.semarthrit.2018.05.010","DOI":"10.1016\/j.semarthrit.2018.05.010"},{"key":"2025090312360572000_5.1.e000806.32","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4103\/jpcs.jpcs_31_17","article-title":"Number needed to treat","volume":"3","author":"Biswas","year":"2017","journal-title":"J Pract Cardiovasc Sci"},{"key":"2025090312360572000_5.1.e000806.33","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205056"},{"key":"2025090312360572000_5.1.e000806.34","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1002\/acr.22044","article-title":"Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial","volume":"65","author":"Kavanaugh","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2025090312360572000_5.1.e000806.35","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22256"},{"key":"2025090312360572000_5.1.e000806.36","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-209055"},{"key":"2025090312360572000_5.1.e000806.37","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.098202"},{"key":"2025090312360572000_5.1.e000806.38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210242"},{"key":"2025090312360572000_5.1.e000806.39","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T"},{"key":"2025090312360572000_5.1.e000806.40","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7525-7-25","article-title":"The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people","volume":"7","author":"Salaffi","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"2025090312360572000_5.1.e000806.41","unstructured":"Li X , Jesson M , Lee J , et al . Characterization of a potent inhibitor of JAK kinases, CP-690,550, and inhibition of specific JAK\/STAT pathways at efficacious exposures in a rodent model of arthritis. Chantilly, Virginia: 15th International Inflammation Research Association Conference, 2008."},{"key":"2025090312360572000_5.1.e000806.42","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3892\/br.2012.42","article-title":"TNF inhibitor therapy for rheumatoid arthritis","volume":"1","author":"Ma","year":"2013","journal-title":"Biomed Rep"},{"key":"2025090312360572000_5.1.e000806.43","doi-asserted-by":"publisher","DOI":"10.1038\/nri1184"},{"key":"2025090312360572000_5.1.e000806.44","doi-asserted-by":"crossref","DOI":"10.1186\/1476-9255-7-41","article-title":"Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis","volume":"7","author":"Meyer","year":"2010","journal-title":"J Inflamm (Lond)"},{"key":"2025090312360572000_5.1.e000806.45","article-title":"Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumor necrosis factor inhibitors in the phase III, randomized, controlled trial: OPAL Beyond","volume":"4","author":"Strand","year":"2018","journal-title":"RMD Open"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2018-000806","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:36:15Z","timestamp":1756928175000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2018-000806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,11]]},"published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1136\/rmdopen-2018-000806"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2018-000806","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}